Elli Lilly Reports Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) in P-III BLAZE-1 Study for the Prevention of COVID-19

March 11, 2021 Auto Bot bamlanivimab, Clinical Trials, etesevimab, Prevention, reports, results 0

Shots:

  • The P-III BLAZE-1 study involves assessing Bamlanivimab (700 mg) + Etesevimab (1400 mg) vs PBO in 769 COVID-19 patients aged ≥12yrs. who are at high risk for progressing to severe COVID-19 and/or hospitalization
  • The results demonstrated an 87% reduction in hospitalizations and death with significant improvements in 2EPs
  • The data support the use of the dose recently authorized FDA’s EUA and EMA’s CHMP positive opinion. The results are consistent with those seen in other data sets from P-I, P-II and P-III trials evaluating these antibodies

Click here ­to­ read full press release/ article | Ref: Lilly | Image: France Info

The post Elli Lilly Reports Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) in P-III BLAZE-1 Study for the Prevention of COVID-19 first appeared on PharmaShots.